Glibenclamide modulates glucantime activity and disposition in Leishmania major

Experimental Parasitology

Volumn 121, Issue 4, 2009, Pages 331-337

  Padrón Nieves, Maritza ^a   Díaz, Emilia ^a   Machuca, Claudia ^a   Romero, Amarilis ^a   Sucre, Alicia Ponte ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Drug activity combination therapy; Glibenclamide ABC transporter; Leishmania major glucantime

Indexed keywords

ABC TRANSPORTER; AMPHOTERICIN B; GLIBENCLAMIDE; MEGLUMINE ANTIMONATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ORGANELLE; CONTROLLED STUDY; CYTOPLASM; DRUG ACTIVITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; ELECTRON MICROSCOPY; INFECTION RATE; LEISHMANIA MAJOR; LEISHMANIASIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; DRUG SYNERGISM; GLYBURIDE; LEISHMANIA MAJOR; MACROPHAGES, PERITONEAL; MEGLUMINE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; ORGANOMETALLIC COMPOUNDS;

LEISHMANIA MAJOR;

EID: 60849105058     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2008.12.008     Document Type: Article

References (48)

1. Becq F., Hamon Y., Bajetto A., Gola M., Verrier B., and Chimini G. ABC1, an ATP binding cassette transporter required for phagocytosis of apoptotic cells, generates a regulated anion flux after expression in Xenopus laevis oocytes. Journal of Biological Chemistry 272 (1997) 2695-2699
2. Callahan H.L., Portal A.C., Devereaux R., and Grogl M. An axenic amastigote system for drug screening. Antimicrobial Agents and Chemotherapy 41 (1997) 818-822
3. Choudhury K., Zander D., Kube M., Reinhardt M., and Clos J. Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII. International Journal of Parasitology 38 (2008) 1411-1423
4. Coelho A.C., Yamashiro-Kanashiro E.H., Bastos S.F., Mortara R.A., and Cotrim P.C. Intracellular location of the ABC transporter PRP1 related to pentamidine resistance in Leishmania major. Molecular and Biochemical Parasitology 150 (2006) 378-383
5. Conseil G., Deeley R.G., and Cole S.P. Role of two adjacent cytoplasmic tyrosine residues in MRP1 (ABCC1) transport activity and sensitivity to sulfonylureas. Biochemical Pharmacology 69 (2005) 451-461
6. Croft, S.L., Yardley, V., Kendrick, H., 2002. Field epidemiology. In: Drug sensitivity of Leishmania species: some unresolved problems. Transactions of the Royal Society of Tropical Medicine and Hygyene, 96, S1127-S1129.
7. Croft S.L., Seifert K., and Yardley V. Current scenario of drug development for leishmaniasis. Indian Journal of Medical research 123 (2006) 399-410
8. Davis A.J., Murray H.W., and Handman E. Drugs against leishmaniasis: a synergy of technology and partnerships. Trends in Parasitology 20 (2004) 73-76
9. El Fadili K., Messier N., Leprohon P., Roy G., Guimond C., Trudel N., Saravia N.G., Papadopoulou B., Légaré D., and Ouellette M. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrobial Agents and Chemotherapy 49 (2005) 1988-1993
10. 3 (edelfosine) and amphotericin B. Acta Tropica 81 (2002) 151-157
11. Frezard F., Demicheli C., Ferreira C., and Costa M.A. Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrobial Agents and Chemotherapy 45 (2001) 913-916
12. García N., Figarella K., Mendoza-León A., and Ponte-Sucre A. Changes in the infectivity, pyruvate kinase and acid phosphatase activity and P-glycoprotein expression in glibenclamide resistant Leishmania mexicana. Parasitology Research 86 (2000) 99-904
13. Gayet L., Picault N., Cazalé A.C., Beyly A., Lucas P., Jacquet H., Suso H.P., Vavasseur A., Peltier G., and Forestier C. Transport of antimony salts by Arabidopsis thaliana protoplasts over-expressing the human multidrug resistance-associated protein 1 (MRP1/ABCC1). FEBS Letters 580 (2006) 6891-6897
14. Golstein P.E., Boom A., Van Geffel J., Jacobs P., Maseret B., and Beauwens R. P-glycoprotein inhibition by glibenclamide and related compounds. Pfluggers Archives 437 (1999) 652-660
15. Gourbal B., Sonuc N., Bhattacharjee H., Légaré D., Sundar S., Ouellette M., Rosen B.P., and Mukhopadhyay R. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J. Biol. Chem. 279 (2004) 3101-3107
16. Hamon Y., Luciani M.F., Becq F., Verrier B., Rubartelli A., and Chimini G. Interleukin-1 beta secretion is impaired by inhibitors of the ATP binding cassette transporter, ABC1. Blood 90 (1997) 2911-2915
17. Haskó G., Deitch E.A., Németh Z.H., Kuhel D.G., and Szabó C. Inhibitors of ATP-binding cassette transporters suppress interleukin-12 p40 production and major histocompatibility complex II up-regulation in macrophages. Journal of Pharmacology and Experimental Therapeutics 301 (2002) 103-110
18. ATP: an inward rectifier sub-unit plus the sulfonylurea receptor. Science 270 (1995) 1166-1169
19. Laurent T., Rijal S., Yardley V., Croft S., De Doncker S., Decuypere S., Khanal B., Singh R., Schönian G., Kuhls K., Chappuis F., and Dujardin J.C. Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal. Infection, Genetics and Evolution 7 (2007) 206-212
20. Lee E.K., Kwon M., Ko J.H., Yi H., Hwang M.G., Chang S., and Cho M.H. Binding of sulfonylurea by AtMRP5, an Arabidopsis multidrug resistance-related protein that functions in salt tolerance. Plant Physiology 134 (2004) 528-538
21. Légaré D., Hettema E., and Ouellette M. The P-glycoprotein-related gene family in Leishmania. Molecular and Biocheical Parasitology 68 (1994) 81-91
22. Leonard G.D., Fojo T., and Bates S.E. The role of ABC transporters in clinical practice. Oncologist 8 (2003) 411-424
23. Loiseau P.M., and Bories C. Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target identification and design of antileishmanial modulators. Current Topics in Medicinal Chemistry 6 (2006) 539-550
24. Machuca C., Rodríguez A., Herrera M., Silva S., and Ponte-Sucre A. Metabolic adaptations induced by resistance to glibenclamide in Leishmania amazonensis. Experimental Parasitology 114 (2006) 1-9
25. Ménez C., Buyse M., Besnard M., Farinotti R., Loiseau P., and Barratt G. Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro. Antimicrobial Agents and Chemotherapy 50 (2006) 3793-3800
26. Mookerjee Basu J., Mookerjee A., Banerjee R., Saha M., Singh S., Naskar K., Tripathy G., Sinha P.K., Pandey K., Sundar S., Bimal S., Das P.K., Choudhuri S.K., and Roy S. Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection. Antimicrobial Agents and Chemotherapy 52 (2008) 1080-1093
27. Ouellette M., Légaré D., Haimeur A., Grondin K., Roy G., Brochu C., and Papadopaulou B. ABC transporters in Leishmania and their role in drug resistance. Drug Resistance Update 1 (1998) 43-48
28. Ouellette M., Drummelsmith J., and Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resistance Update 7 (2004) 257-266
29. Pérez-Victoria F.J., Sánchez-Cañete M.P., Seifert K., Croft S.L., Sundar S., Castanys S., and Gamarro F. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resistance Update 9 (2006) 26-39
30. Ponte-Sucre A., Campos Y., Vasquez J., Moll H., and Mendoza-León A. Sensitivity of Leishmania spp. to glibenclamide and 4-aminopyridine: a tool for the study of drug resistance development. Memorias Instituto Oswaldo Cruz 92 (1997) 601-606
31. Ponte-Sucre A.I., Campos Y., Fernández M., Moll H., and Mendoza-León A. Leishmania sp.: growth and survival of Leishmania sp. are impaired by ion channel blockers. Experimental Parasitology 88 (1998) 11-19
32. Ponte-Sucre A., Figarella K., and Moll H. Experimental Leishmaniasis: the glibenclamide-triggered decrease in parasite growth correlates with changes in macrophage features. Inmunopharmacology Immunotoxicology 23 (2001) 477-486
33. Ponte-Sucre, A. 2003. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplast. Biol. Dis. 2, 14. Available from: .
34. Ponte-Sucre A., Vicik R., Schultheis M., Schirmeister T., and Moll H. Aziridine-2,3-dicarboxylates: peptidomimetic cysteine protease inhibitors with antileishmanial activity. Antimicrobial Agents and Chemotherapy 50 (2006) 2439-2447
35. Pujals G., Suñé-Negre J.M., Pérez P., García E., Portus M., Tico J.R., Miñarro M., and Carrió J. In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum. Parasitology Research 102 (2008) 1243-1247
36. Ramos H., Valdivieso E., Gamargo M., Dagger F., and Cohen B. Amphotericin B kills unicellular Leishmania by forming aqueous pores permeable to small cations and anions. Journal of Membrane Biology 152 (1996) 65-75
37. Roberts W.L., McMurray W.J., and Rainey P.M. Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime). Antimicrobial Agents and Chemotherapy 42 (1998) 1076-1082
38. Saugar J.M., Delgado J., Hornillos V., Luque-Ortega J.R., Amat-Guerri F., Acuña A.U., and Rivas L. Synthesis and biological evaluation of fluorescent leishmanicidal analogues of hexadecylphosphocholine (miltefosine) as probes of antiparasite mechanisms. Journal of Medicinal Chemistry 50 (2007) 5994-6003
39. Sauna Z.E., Smith M.M., Müller M., Kerr K.M., and Ambudkar S.V. The mechanism of action of multidrug-resistance-linked P-glycoprotein. Journal of Bioenergy and Biomembranes 33 (2001) 481-491
40. Schultz B., DeRoos A., Venglarik C., Singh A., Frizzell R., and Bridges R. Glibenclamide blockade of CFTR chloride channels. American Journal of Physiology 271 (1996) L192-L200
41. Seifert K., and Croft S.L. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicroialb Agents and Chemotherapy 50 (2006) 73-79
42. +(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrobial Agents and Chemotherapy 50 (2006) 4214-4216
43. Shaked-Mishan P., Ulrich N., Ephros M., and Zilberstein D. Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. Journal of Biological Chemistry 276 (2001) 3971-3976
44. Silva N., Camacho N., Figarella K., and Ponte-Sucre A. Cell differentiation and infectivity of Leishmania mexicana are inhibited in an ABC-transporter blocker resistant strain. Parasitology 128 (2004) 629-634
45. Singh N. Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian Journal of Medical Research 123 (2006) 411-422
46. Ueda K., Matsuo M., Tanabe K., Morita K., Kioka N., and Amachi T. Comparative aspects of the function and mechanism of SUR1 and MDR1 proteins. Biochimica and Biophysica Acta 1461 (1999) 305-313
47. Uzcátegui N.L., Figarella K., Camacho N., and Ponte-Sucre A. Substrate preferences and glucose uptake in glibenclamide-resistant Leishmania parasites. Comparative Biochemistry and Physiology 140 (2005) 395-402
48. + channels in mouse pancreatic beta cells: against a role in organelle cation homeostasis. Diabetologia 49 (2006) 1567-1577